[go: up one dir, main page]

WO2013032230A3 - Pharmaceutical angiogenic composition including a microrna-382 activator - Google Patents

Pharmaceutical angiogenic composition including a microrna-382 activator Download PDF

Info

Publication number
WO2013032230A3
WO2013032230A3 PCT/KR2012/006909 KR2012006909W WO2013032230A3 WO 2013032230 A3 WO2013032230 A3 WO 2013032230A3 KR 2012006909 W KR2012006909 W KR 2012006909W WO 2013032230 A3 WO2013032230 A3 WO 2013032230A3
Authority
WO
WIPO (PCT)
Prior art keywords
microrna
activator
pharmaceutical
angiogenic composition
composition including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/006909
Other languages
French (fr)
Korean (ko)
Other versions
WO2013032230A2 (en
Inventor
이유미
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of KNU
Original Assignee
Industry Academic Cooperation Foundation of KNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of KNU filed Critical Industry Academic Cooperation Foundation of KNU
Priority to US14/240,530 priority Critical patent/US9051620B2/en
Priority claimed from KR1020120094792A external-priority patent/KR20130024830A/en
Publication of WO2013032230A2 publication Critical patent/WO2013032230A2/en
Publication of WO2013032230A3 publication Critical patent/WO2013032230A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an angiogenic composition, and more particularly, to a pharmaceutical angiogenic composition including a microRNA-382 activator. The inventors of the present invention have confirmed that microRNA-382, the expression of which is elevated in stomach cancer cells in a low oxygen environment, affects the promotion of angiogenesis. Therefore, provided in the present invention is the pharmaceutical angiogenic composition which includes the microRNA-382 activator, which is angiogenic and thus promotes cell proliferation, and can be valuably used in treating injuries, ischemic myocardial infarctions, or foot ischemia.
PCT/KR2012/006909 2011-08-30 2012-08-29 Pharmaceutical angiogenic composition including a microrna-382 activator Ceased WO2013032230A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/240,530 US9051620B2 (en) 2011-08-30 2012-08-29 Pharmaceutical angiogenic composition including a microRNA-382 activator

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110086986 2011-08-30
KR10-2011-0086986 2011-08-30
KR1020120094792A KR20130024830A (en) 2011-08-30 2012-08-29 Pharmaceutical composition comprising microrna-382 activator for promoting angiogenic activity
KR10-2012-0094792 2012-08-29

Publications (2)

Publication Number Publication Date
WO2013032230A2 WO2013032230A2 (en) 2013-03-07
WO2013032230A3 true WO2013032230A3 (en) 2013-05-10

Family

ID=47757053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006909 Ceased WO2013032230A2 (en) 2011-08-30 2012-08-29 Pharmaceutical angiogenic composition including a microrna-382 activator

Country Status (1)

Country Link
WO (1) WO2013032230A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014008A2 (en) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
KR20100009268A (en) * 2008-07-18 2010-01-27 국립암센터 Anti-cancer composition comprising microrna molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014008A2 (en) * 2006-07-28 2008-01-31 The Johns Hopkins University Compositions and methods for modulating angiogenesis
KR20100009268A (en) * 2008-07-18 2010-01-27 국립암센터 Anti-cancer composition comprising microrna molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM, MIN JEONG: "The roles of microRNA-382 induced by hypoxia in angiogenesis", MASTER'S THESIS, KYUNKPOOK NATIONAL UNIVERSITY GRADUATE SCHOOL, June 2010 (2010-06-01) *
SUAREZ ET AL.: "MicroRNAs as novel regulators of angiogenesis", CIRCULATION RESEARCH, vol. 104, 2009, pages 442 - 454, XP008108165, DOI: doi:10.1161/circresaha.108.191270 *

Also Published As

Publication number Publication date
WO2013032230A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
PE20140616A1 (en) COMPOSITION INCLUDING AFLIBERCEPT, FOLINIC ACID, 5-FLUOROURACILO (5-FU) AND IRINOTECAN (FOLFIRI)
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
EA026892B9 (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
IN2014DN06104A (en)
MA37400A1 (en) Cyclil compounds are not heterogeneous as mek inhibitors
MX356958B (en) Glucagon-like-peptide-2 (glp-2) analogues.
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
PH12013500441A1 (en) Materials and methods for improving gastrointestinal function
WO2012104007A3 (en) 7-azaindole derivatives
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
TW201611843A (en) Methods of treatment with arginine deiminase
GB201316021D0 (en) Vitamin D composition
MX2020014208A (en) Optimised subcutaneous therapeutic agents.
HUE043546T2 (en) use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis.
IN2012DE00497A (en)
MX2015003343A (en) TREATMENT COMBINED WITH THE NETRINA-1 INTERFERENCE PHARMACO AND THE CHEMOTHERAPEUTIC PHARMACO.
TR201009167A2 (en) Pharmaceutical granules containing cephalosporin.
EP2611799A4 (en) Pharmaceutical compositions of linezolid
MX345414B (en) SYNERGIC ANTIOXIDANT COMPOSITION.
WO2013032230A3 (en) Pharmaceutical angiogenic composition including a microrna-382 activator
WO2011103382A3 (en) Compositions and methods for inducing angiogenesis
WO2014104989A8 (en) Pharmaceutical compositions comprising aripiprazole
MX2014010749A (en) Gynecologic composition to treat vulvar vestibulitis.
WO2013025074A3 (en) Anticancer or antioxidant composition containing quamoclit pennata extract or compound derived from quamoclit pennata extract
WO2013032231A3 (en) Pharmaceutical anti-angiogenic composition including a microrna-382 inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12828384

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14240530

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12828384

Country of ref document: EP

Kind code of ref document: A2